HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Kohji Fukunaga Selected Research

UCF 101

1/2008Activation of HtrA2, a mitochondrial serine protease mediates apoptosis: current knowledge on HtrA2 mediated myocardial ischemia/reperfusion injury.
2/2007Inhibition of HtrA2/Omi ameliorates heart dysfunction following ischemia/reperfusion injury in rat heart in vivo.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Kohji Fukunaga Research Topics

Disease

38Ischemia
10/2019 - 08/2002
24Brain Ischemia (Cerebral Ischemia)
05/2021 - 07/2005
22Alzheimer Disease (Alzheimer's Disease)
07/2022 - 02/2007
22Hypertrophy
07/2016 - 12/2007
18Cognitive Dysfunction
01/2021 - 04/2011
15Parkinson Disease (Parkinson's Disease)
06/2022 - 01/2019
12Neurodegenerative Diseases (Neurodegenerative Disease)
07/2022 - 06/2011
11Embolism (Embolus)
01/2019 - 09/2005
11Cardiomegaly (Heart Hypertrophy)
01/2014 - 01/2009
10Synucleinopathies
06/2022 - 01/2019
9Memory Disorders (Memory Loss)
01/2020 - 07/2008
9Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
10/2019 - 09/2003
9Heart Failure
07/2016 - 05/2009
8Infarction (Infarctions)
08/2008 - 12/2004
6Inflammation (Inflammations)
05/2021 - 04/2016
6Schizophrenia (Dementia Praecox)
07/2019 - 09/2006
6Cardiovascular Diseases (Cardiovascular Disease)
07/2013 - 01/2008
6Myocardial Infarction
01/2012 - 12/2004
5Mitochondrial Diseases (Mitochondrial Disease)
02/2022 - 07/2016
5Reperfusion Injury
05/2021 - 12/2004
5Aortic Valve Stenosis (Aortic Stenosis)
08/2011 - 12/2007
5Myocardial Ischemia (Ischemic Heart Diseases)
05/2009 - 10/2007
4Autistic Disorder (Autism)
11/2022 - 01/2014
4Dementia (Dementias)
06/2022 - 01/2017
4Intellectual Disability (Idiocy)
01/2021 - 01/2011
4Neoplasms (Cancer)
12/2020 - 07/2003
4Body Weight (Weight, Body)
04/2019 - 12/2007
4Brain Edema (Cerebral Edema)
10/2009 - 10/2006
3Glioma (Gliomas)
12/2020 - 05/2003
3Autism Spectrum Disorder
10/2020 - 03/2016
3Neuroblastoma
02/2020 - 10/2009
3Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder)
07/2019 - 01/2018
3ATR-X syndrome
09/2018 - 06/2011
3Ischemic Stroke
07/2018 - 02/2012
3Stroke (Strokes)
07/2018 - 08/2008
3Catalepsy
04/2018 - 02/2010
3Learning Disabilities (Learning Disability)
01/2018 - 04/2006
3Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease)
02/2017 - 01/2014
3Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy)
12/2016 - 02/2012
3Brain Injuries (Brain Injury)
04/2016 - 08/2003
3Hypertension (High Blood Pressure)
01/2012 - 05/2009

Drug/Important Bio-Agent (IBA)

25Proteins (Proteins, Gene)FDA Link
01/2021 - 07/2003
23Calcium-Calmodulin-Dependent Protein Kinase Type 2IBA
06/2021 - 09/2002
16SynucleinsIBA
06/2022 - 01/2019
11Sigma-1 ReceptorIBA
09/2018 - 11/2009
10Fatty Acid Binding Protein 3IBA
03/2022 - 02/2010
9Adenosine Triphosphate (ATP)IBA
10/2019 - 06/2011
9Fas Ligand Protein (Fas Ligand)IBA
07/2012 - 08/2002
93- (2- (4- (3- chloro- 2- methylphenyl)1- piperazinyl)ethyl)5,6- dimethoxy- 1- (4- imidazolylmethyl)- 1H- indazol dihydrochloride 3.5 hydrateIBA
02/2010 - 09/2004
8Dopamine (Intropin)FDA LinkGeneric
03/2022 - 10/2009
8Cholinergic Agents (Cholinergics)IBA
01/2022 - 04/2011
8T-Type Calcium Channels (T-Type Calcium Channel)IBA
06/2021 - 09/2017
8LigandsIBA
03/2021 - 10/2015
8Neuroprotective AgentsIBA
04/2019 - 09/2003
7SodiumIBA
01/2018 - 08/2002
7Vanadates (Orthovanadate)IBA
01/2018 - 08/2002
7Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA
01/2017 - 03/2004
6MelatoninIBA
10/2020 - 04/2011
6SA 4503IBA
10/2019 - 01/2013
6Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA
10/2019 - 03/2008
6Pharmaceutical PreparationsIBA
01/2019 - 04/2007
6Tyrosine (L-Tyrosine)FDA Link
01/2018 - 06/2005
6Calmodulin (Calcium-Dependent Activator Protein)IBA
12/2016 - 06/2005
6CalcineurinIBA
01/2011 - 07/2006
5Fatty Acid-Binding ProteinsIBA
02/2022 - 04/2011
5Nootropic Agents (Nootropics)IBA
07/2019 - 07/2008
5Calcium-Calmodulin-Dependent Protein KinasesIBA
07/2019 - 09/2006
5Angiotensin IIIBA
07/2016 - 12/2007
5Dehydroepiandrosterone (DHEA)IBA
10/2015 - 11/2009
5Fluvoxamine (Luvox)FDA LinkGeneric
01/2014 - 10/2010
5Nitric Oxide (Nitrogen Monoxide)FDA Link
07/2013 - 09/2005
5CalpainIBA
01/2011 - 05/2006
4Phosphotransferases (Kinase)IBA
06/2022 - 08/2002
4EnzymesIBA
06/2022 - 09/2004
4Peroxynitrous Acid (Peroxynitrite)IBA
11/2021 - 04/2007
4Cyclopentanes (Cyclopentane)IBA
06/2021 - 01/2018
4pyridineIBA
01/2021 - 07/2008
41- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA
01/2020 - 02/2012
4AntioxidantsIBA
01/2020 - 07/2014
4Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA
12/2019 - 02/2007
4Proto-Oncogene Proteins c-akt (Protein Kinase B)IBA
10/2019 - 09/2006
4Antipsychotic Agents (Antipsychotics)IBA
07/2019 - 10/2009
4Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA
01/2014 - 11/2010
4oxovanadium IVIBA
01/2012 - 10/2008
4Vanadium CompoundsIBA
05/2009 - 03/2008
4Forkhead Transcription Factors (Forkhead Box Proteins)IBA
01/2009 - 08/2002
3Tyrosine 3-Monooxygenase (Tyrosine Hydroxylase)IBA
02/2022 - 03/2020
3Amyloid (Amyloid Fibrils)IBA
01/2021 - 01/2020
3U 0126 (UO 126)IBA
01/2020 - 01/2009
3Messenger RNA (mRNA)IBA
10/2019 - 04/2008
3Amyloid beta-PeptidesIBA
02/2019 - 10/2009
3N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA
01/2017 - 02/2007
3Haloperidol (Haldol)FDA LinkGeneric
07/2016 - 02/2010
3N-Methylaspartate (NMDA)IBA
01/2011 - 02/2007
3DystrophinIBA
02/2010 - 12/2007
3IndazolesIBA
02/2010 - 06/2005

Therapy/Procedure

23Therapeutics
06/2021 - 09/2006
11Microspheres (Microsphere)
01/2019 - 09/2005
5Ovariectomy (Oophorectomy)
08/2011 - 12/2007
3Oral Administration
07/2013 - 07/2008